Company news
Teijin Limited (TSE:3401) news
Every Teijin Limited press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Summary of Consolidated Financial Results for the Three Months Ended June 30, 2026[IFRS]
August 3, 2026
(Update)Notice on Conclusion of Merger Agreement Concerning Business Integration Between Teijin Frontier Co., Ltd. and Asahi Kasei Advance Corporation
July 30, 2026
Notice Concerning Sale of Shares Held by Untraceable Shareholders
July 29, 2026
Notice Concerning Completion of Payment for the Disposal of Treasury Shares as “Restricted Stock” and “Performance Share Units”
July 15, 2026
(Correction) Partial Corrections of the “Notice Concerning the Disposal of Treasury Shares as Restricted Stock and Performance Share Units”
June 30, 2026
Notice Regarding Dividend Received from a Consolidated Subsidiary
June 26, 2026
Teijin Receives Approval for Additional Indications of XEOMIN for Cervical Dystonia and Blepharospasm in Japan
June 22, 2026
Notice of the Results of the Exercise of Voting Rights at the 160th Ordinary General Meeting of Shareholders
June 19, 2026
Teijin : Notice regarding Recording of Impairment Loss, Gain on Sale of Shares of Affiliates (Consolidated) and Extraordinary Income and Loss (Non-consolidated)
May 10, 2026
Teijin : J-TEC Announces Application for Marketing Approval for the World's First Dried Allogeneic Cultured Epidermis
March 26, 2026
Teijin : Notice Regarding Dividend Received from a Consolidated Subsidiary
March 17, 2026
Teijin : Regenet Begins Full-scale Operations at Expanded Iwakuni Factory Providing Regenerative Medicine CDMO Services to Global Customers
March 10, 2026
Teijin : Pharma and Aska Pharmaceutical Enter Joint Research Agreement to Accelerate Discovery of Novel Small-Molecule Drug Candidates for Gynecological Diseases
February 16, 2026
Teijin : Pharma Limited Applies for Manufacturing and Marketing Approval in Japan for New Weekly Pediatric Growth Hormone Deficiency Treatment
February 11, 2026
Teijin : Japan Tissue Engineering Wins Approval for Insurance Coverage of JACC,Its First-in-Japan Therapy for Autologous Cartilage Repair in Knee Osteoarthritis
January 21, 2026
Asahi Kasei Advance and Teijin Frontier to Integrate Businesses for Sustainable Growth
December 1, 2025
Teijin : Pharma to Receive $5 Million Milestone Payment from Bioprojet for Initiating Phase 1 Clinical Trial of Narcolepsy Drug Candidate
November 26, 2025